Amryt Pharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Amryt Pharma generated cash of $26,891,000, which is more than the previous year. Cash used in financing activities reached the amount of $26,028,000 last year. Net change in cash is therefore $51,569,000.
Cash Flow
| 2010 | -256.19K | 107K | -129.60K |
|---|---|---|---|
| 2011 | -286.04K | 287.65K | 0 |
| 2012 | -395.44K | 632.39K | 0 |
| 2016 | -6.42M | 2.58M | 12.35M |
| 2017 | -14.23M | -379.10K | 29.20M |
| 2018 | -14.94M | -242.50K | 3.17M |
| 2019 | -37.49M | 24.42M | 65.94M |
| 2020 | 26.89M | -1.50M | 26.02M |
AMYT.L Cash Flow Statement (2010 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 67.22M | 11.22M | 23.46M | 9.92M | 179.84K | 1.6K | 0 | 274.28K |
Operating activities | ||||||||
Net income | -104.52M | -65.53M | -29.48M | -31.35M | -8.20M | -826.11K | -3.05M | -123.57K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 44.46M | 12.65M | 354.60K | 310.72K | 204.03K | 0 | 99.63K | 147.69K |
Stock-based compensation expense | 4.72M | 841K | 793.86K | 677.83K | 240.83K | 0 | 0 | 0 |
| Deferred income tax benefit | 4.72M | 841K | 793.86K | 677.83K | 240.83K | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | -10.60M | -5.89M | -897.96K | -375.50K | -87.29K | 0 | 0 | 0 |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | 26.89M | -37.49M | -14.94M | -14.23M | -6.42M | -395.44K | -286.04K | -256.19K |
Investing activities | ||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -2.46M | -652K | -227.63K | -395.90K | -12.62K | 0 | 0 | -7.53K |
Acquisitions Net | 0 | 24.98M | 0 | 0 | 1.84M | 0 | 0 | 0 |
Cash generated by investing activities | -1.50M | 24.42M | -242.50K | -379.10K | 2.58M | 632.39K | 287.65K | 107K |
Financing activities | ||||||||
Common Stock Issued | 37.92M | 63.00M | 0 | 17.26M | 11.83M | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | -49.42K | 0 | 0 | 0 |
Cash used in financing activities | 26.02M | 65.94M | 3.17M | 29.20M | 12.35M | 0 | 0 | -129.60K |
Net Change In Cash | 51.56M | 56.00M | -12.24M | 14.68M | 8.51M | 236.94K | 0 | -232.08K |
Cash at end of period | 118.79M | 67.22M | 11.22M | 24.60M | 8.69M | 238.54K | 1.60K | 42.19K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |